Zenith Epigenetics Emerges from Resverlogix Spin Out
Zenith Epigenetics Corp., an early-stage company resulting from the spin out of RVX Therapeutics Inc. from Resverlogix Corp., has commenced operations. The company is focused on developing drugs using its epigenetics platform. As part of the spin-out, Resverlogix transferred RVX debts to Zenith, as well as $10 million for initial capitalization. Calgary's publicly-listed Resverlogix has been backed by U.S. venture capital NGN Capital since April 2009.
3 June 2013•3 mins read
